Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Medtronic Announces FDA Classification of Deep Brain Stimulation Lead Cap Communication


Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-05-02 23:02:02 -

MINNEAPOLIS - May 2, 2013 - In keeping with its commitment to keep physicians
informed about product performance and safety, Medtronic, Inc. (NYSE: MDT)
issued an Urgent Medical Device Correction notification in February 2013 to
provide physicians with information concerning the potential for deep brain
stimulation (DBS) lead damage associated with the use of the lead cap provided
in Medtronic DBS lead kits and dystonia therapy kits. The U.S. Food and Drug
Administration (FDA) has classified the communication as a Class I Recall.

Medtronic has received reports of DBS leads being damaged due to twisting of the
connector within the lead cap during the surgical procedure. The DBS lead cap is
included in DBS lead kits and dystonia therapy kits and is sometimes used
temporarily to protect the end of 
a DBS lead after it has been implanted. The DBS lead cap is not used in all DBS procedures, and is not permanently implanted.  Depending on the extent of lead damage due to twisting of the connector during the placement and removal of the lead cap, lead replacement may be required or optimal therapy may not be achieved. In the case of lead damage, if at the beginning of therapy patients are receiving therapy as expected, they are not likely to be affected by this issue. Patients with questions relating to this issue are encouraged to talk with their physicians. A manufacturing change intended to address the issue is currently under FDA review, and in the meantime Medtronic has issued modified instructions to physicians who may use DBS lead caps. Any malfunctions or adverse events related to a device should be reported to Medtronic Neuromodulation Technical Services at 1-800-707-0933, weekdays from 7 a.m. to 6 p.m. CST, and the FDA's MedWatch Program at www.fda.gov/MedWatch. About Medtronic DBS Therapy DBS therapy uses a surgically implanted medical device, similar to a pacemaker, to deliver mild electrical pulses to precisely targeted areas of the brain. The therapy is currently approved in many locations around the world, including Europe and the United States, for the treatment of the disabling symptoms of essential tremor, advanced Parkinson's disease and chronic intractable primary dystonia, for which approval in the United States is under a Humanitarian Device Exemption (HDE). In Europe, Canada and Australia, DBS therapy is approved for the treatment of refractory epilepsy. The therapy is also approved for the treatment of severe, treatment-resistant obsessive-compulsive disorder in the European Union and in the United States under an HDE. About Medtronic Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. - end - Contacts: Justin Ihle Public Relations +1-763-526-0911 Jeff Warren Investor Relations +1-763-505-2696 This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Medtronic, Inc. via Thomson Reuters ONE [HUG#1698919]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser